Gyre TherapeuticsGYRE +1.29%39 FCF Margin % is 13.31% as of Mar. 2026, which is 140% above its 10-year median of 5.55. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.82 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Gyre Therapeutics ranks better than 76.64% on this metric.
The historical rank and industry rank for Gyre Therapeutics's FCF Margin % or its related term are showing as below:
GYRE'
s FCF Margin % Range Over the Past 10 Years
Min: -6.4 Med: 5.55 Max: 15.25
Current: 2.59
During the past 5 years, the highest FCF Margin % of Gyre Therapeutics was 15.25%. The lowest was -6.40%. And the median was 5.55%.
GYRE's FCF Margin % is ranked better than 76.64% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs GYRE: 2.59
Gyre Therapeutics FCF Margin % Related Terms
Gyre Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gyre Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (GYRE) has a FCF Margin % of 13.31% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gyre Therapeutics and its competitors. This is 140% above median its historical median of 5.55. According to the industry distribution chart, Gyre Therapeutics ranks #224 out of 959 companies in the Biotechnology industry, placing it in the top 23.4%.
Is Gyre Therapeutics' FCF Margin % too high?
Gyre Therapeutics' current FCF Margin % of 13.31% is 140% above median its 10-year median of 5.55. Based on the distribution chart, Gyre Therapeutics ranks #224 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' FCF Margin % compare to CBIO and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #224 out of 959 companies for FCF Margin %. This places Gyre Therapeutics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current FCF Margin % is 13.31%, which is 140% above median its own 10-year median of 5.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.82, compared to a current price of $6.30 — trading 35.8% below its estimated fair value. The current FCF Margin % is 13.31%, which is 140% above median its 10-year median of 5.55. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current FCF Margin % is 13.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.30 is trading 35.8% below its estimated GF Value™ of $9.82.
GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.
Key valuation signals for GYRE:
FCF Margin %: 13.31% (140% above median its 10-year median of 5.55)
GF Value™: $9.82 vs. price of $6.30 (35.8% below fair value)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
